
    
      A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study
      of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination
      with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers.
    
  